TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03564691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered IV Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830A
Description: MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
Study: NCT02475031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAP-C
Description: TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAP-S
Description: Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
Study: NCT01101165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 40-mg tablet x 1 dose taken without food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
Study: NCT04643353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative vaginal Erbium YAG laser treatment
Description: Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia) with SMOOTH mode setting, which enables non-ablative, thermal-only operation. The parameters are selected based on extensive preclinical and clinical studies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFE
Description: PFE will be prescribed as it is already implemented in clinical practice (i.e. up to 2x 9 sessions with a pelvic floor physiotherapist of choice). Type of physiotherapy, number of completed sessions and duration of therapy will be recorded.
Study: NCT03570892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Description: Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~\*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy
Study: NCT03367572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant/Palonosetron Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant/Palonosetron Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant/Palonosetron Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04635436

Intervention type: OTHER
Group type: OTHER
Intervention: Split-belt treadmill walking.
Description: The intervention will consist of split-belt treadmill walking. During the test session, participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without any support. The test sequence will be the following:~1. Baseline phase. 3 minutes walking at increasing speed, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Habituation phase. 30 seconds walking at 0.2 m s-1.~3. Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~4. Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week.
Study: NCT04300647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT00884312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
Study: NCT04067895

Intervention type: PROCEDURE
Intervention: epiphysiodesis
Description: All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
Study: NCT03412487

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy
Description: under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy
Description: under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.
Study: NCT03367572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02955784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinasprite Mobile App
Description: Mobile App
Study: NCT03441854

Intervention type: DEVICE
Intervention: HFNC group
Description: Application of HFNC oxygen delivery after extubation.
Study: NCT03332940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99M Sulfur Colloid
Description: Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
Study: NCT04051762

Intervention type: DEVICE
Intervention: High flow nasal cannula vs. Nasal continuous positive airway pressure
Description: High flow nasal cannula

Intervention type: DEVICE
Intervention: High flow nasal cannula vs. Nasal continuous positive airway pressure
Description: High flow nasal cannula
Study: NCT01649687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic adult adipose-derived mesenchymal stem cells
Description: Patients will receive intravenously one dose of 5-7x10\^7 cells of allogeneic adipose-derived mesenchymal stem cells
Study: NCT00002942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Study: NCT01129479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill each morning with food for 12 weeks.
Study: NCT01538420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution
Study: NCT01943890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: 1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study: NCT03793777

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia
Description: daily supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily supplementation
Study: NCT04626297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Given SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given SC
Study: NCT04804878

Intervention type: PROCEDURE
Intervention: Collection of blood, tissue, and other biological samples.
Description: Behavioral health assessments, including quality of life.

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Health data abstracted directly from patient's health records
Study: NCT02023398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-9000 HFT
Description: Deep tissue heating with the BTL-9000 HFT for HFT group

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham BTL-9000 HFT
Description: sham deep tissue heating with BTL-9000 HFT in Placebo group
Study: NCT01148784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction
Description: Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction
Description: Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
Study: NCT02363517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)
Description: SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)
Description: SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
Study: NCT02376361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transonic
Description: Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~1. Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~2. Recirculation, access flow will be performed according to HD03 Manual.~3. Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.
Study: NCT00644995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Up Wellness Program
Description: Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
Study: NCT03519932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A toric lens
Description: Contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A toric lens
Description: Contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: samfilcon A toric lens
Description: Contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: samfilcon A toric lens
Description: Contact lens
Study: NCT01658891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Description: beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg
Description: beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
Study: NCT02918175

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mHealth
Description: Personalized step count feedback and medication teaching tool.
Study: NCT03020160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
Study: NCT00318136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
Study: NCT01417000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Study: NCT00318136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
Study: NCT03099421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization
Description: The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
Study: NCT02302027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: platinium IRC9LXO2AWQ
Description: high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 \* 67 \* 36 cm
Study: NCT02617745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet level determination
Description: evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
Study: NCT03988985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-targeted feedback
Description: The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
Study: NCT01417000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03028948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Access ITW

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02741843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Study: NCT03208556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iPD1 CD19 eCAR T cells
Description: iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10\^5 /kg，1×10\^6 /kg，3×10\^6 /kg，and 6×10\^6 CAR T cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide
Description: Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
Study: NCT00945477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Pazopanib 800 mg daily x 12 weeks
Study: NCT00462553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT04108338

Intervention type: OTHER
Intervention: Trial setting
Description: Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.

Intervention type: OTHER
Intervention: Trial setting
Description: Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
Study: NCT02569008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid challenge with Compound Sodium Lactate
Description: Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid challenge with Compound Sodium Lactate
Description: Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid challenge with Compound Sodium Lactate
Description: Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid challenge with Compound Sodium Lactate
Description: Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.